Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPX4-AAV
- Development stage
- Preclinical
- Lead developer
- Jinan University
- Modality
- Gene Therapies
- Administration
- Intraarticular, Intrathecal, Intravenous
01
Overview
GPX4-AAV is an adeno-associated virus (AAV) vector designed to deliver and overexpress the glutathione peroxidase 4 (GPX4) gene. GPX4 is a key antioxidant enzyme that protects cells against ferroptosis by reducing lipid hydroperoxides. GPX4-AAV is primarily utilized in preclinical research to investigate the therapeutic potential of GPX4 overexpression in mitigating ferroptosis-mediated cellular damage in diseases such as diabetic kidney disease (DKD), amyotrophic lateral sclerosis (ALS), and retinal ischemia/reperfusion injury.
- Other names
- AAV-GPX4AAV-GPX-4AAV-GPX 4AAV-mediated GPX4
02
Targets
GPX4 (Glutathione peroxidase 4)
Beyond the preview
Go deeper on GPX4-AAV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPX4-AAV.